Pressure Biosciences Inc PBIO

Technology Scientific & Technical Instruments

Pressure BioSciences, Inc. is engaged in the development and sale of enabling, high pressure technology-based instruments, consumables, and services for the life sciences and other industries worldwide. Its products/services are based on three high-pressure platforms: Ultra Shear Technology (UST), BaroFold Technology (BaroFold), and Pressure Cycling Technology (PCT). The UST platform allows for the creation of stable nanoemulsions of otherwise immiscible oil-based active components in water. It also allows for the preparation of higher quality, homogenized, extended shelf-life or room temperature-stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. PCT utilizes alternating cycles of pressure to control biomolecular interactions (such as cell lysis and biomolecule extraction) safely and reproducibly. The BaroFold platform provides valuable contract services and GMP manufacturing equipment to the biopharmaceutical industry.

OTCQB:PBIO - Post by User

Pressure Biosciences Inc

<< Previous

Bullboard Posts

Next >>

Post by AveragePennyon Dec 22, 2022 1:09pm

85 Views

Post# 35187493

Pressure BioSciences Gives Guidance for Strong Q4 2022 Sales

Future Outlook (The Stage Has Been Set): Q4 2022 & FY 2023.

Revenue
- Q4 2022: PBI expects to report highest quarterly revenue in past 4 years, likely highest ever.
- FY 2023: each quarter expected to exceed prior quarter's revenue. UltraShear revenues expected to top $10M for 2023, beginning with over $1M in Q1 2023.
Agreements (UltraShear Toll Processing)
- Company ending 2022 with 4 executed agreements; very close to final execution of six or more agreements.
- Each agreement estimated to yield $1M or more in incremental annual revenue.
CBD
- Expect data releases in Q1 2023 from key opinion leaders in academia and patient treatment/advocacy, supporting PBI's UltraShear Nano-CBD as among Best-in-Class in Bioavailability globally.
THC
- MA and CA market focus group studies underway to demonstrate expected superior speed of onset and absorption, supporting PBI's UltraShear Nano-THC as among Best-in-Class in Bioavailability globally.
Nutraceutical Supplements
- Supply agreement with several multi-billion-dollar nutraceutical supplement leaders to be closed by mid-2023; strategic investment expected.
Immune Booster
- Discussions underway with quality-leading, top-selling suppliers seeking assistance to nanosize oil-based active ingredients to be included in new, powerful Immune Booster product…including PBI's proven capabilities in curcumin, astaxanthin, and CBD.
Cosmetics:
- PBI anticipates the Dr. Denese SkinScience partnership will strongly leverage data generated in 2022 studies of PBI's UltraShear processed Retinol and Lipid-Soluble Vitamin C, and from current on-going studies, to powerfully validate capabilities of UltraShear-enabled, next-generation, anti-aging serums from Dr. Denese, and will drive new achievements from her existing QVC marketing engine (with over $500M sales over 20 years), starting in Q1 2023.